FESCIOF
10.3.2023 00:11:39 CET | Business Wire | Press release
The Future of Education, Science, and Culture International Organizations Forum (FESCIOF) successfully ended its inaugural convening in Riyadh, uniting for the first time the Arab League Educational, Cultural and Scientific Organization (ALECSO), the Islamic World Educational, Scientific and Cultural Organization (ICESCO), and the United Nations Educational, Scientific and Cultural Organization (UNESCO) plus more than 100 international organizations, leveraging the power of collaboration to drive meaningful impact for the future of international organizations in the fields of education, science, and culture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005847/en/
(from left to right) H.E. Mohamed Ould Amar, Director General, ALECSO, H.E. Dr. Salim Al Malik, ICESCO and Costanza Farina, Director, Regional Bureau for Education in the Arab States – UNESCO Representative to Lebanon and Syria (Photo: AETOSWire)
After the forum concluded, the organizers announced their commitment to facilitate further collaboration among international organizations in education, science, and culture. They affirmed the importance of FESCIOF as an innovative effort to align efforts and maximize positive impact through collaboration. Saudi Arabia also took the initiative to host the next two editions of FESCIOF, in 2025 and 2027.
FESCIOF, which featured more than 20 panel sessions with more than 65 speakers under the theme of “Together for Impact in the 21st Century,” aimed to foster insightful discourse and facilitate knowledge exchange to develop a shared vision and identify opportunities for collaboration.
Alongside high-level representatives from UNESCO, ALECSO, and ICESCO, the event facilitated cross-organizational dialogue within a broad ecosystem of change-makers, featuring speakers and attendees from international organizations, including the Islamic Development Bank (IsDB) Group and the United Nations Development Programme (UNDP), as well as experts and thought leaders in organizational design and management from prestigious academic institutions and prominent organizations, such as Harvard Business School, London Business School, INSEAD Blue Ocean Strategy Institute, Google, and Visa, among others.
The representatives from the education, culture and science international organizations reflected on the discussions during the Forum and highlighted its successes, recognizing the value that partnerships between civil society and the private sector bring to the world. During the final session “Preparing the Ground for Future Collaboration,” the panelists, H.E. Mohamed Ouled Amar, Director General of ALECSO; H.E. Dr. Salim Al-Malik, Director General of ICESCO; Costanza Farina, Director Regional Bureau in Beirut and Representative of UNESCO to Lebanon and Syria, emphasized the need to continue working together to create a “Together for Impact” roadmap to achieve shared goals and create a better future for all.
“As organizations and those who are organizing, we need to work at the right time and the right place because the challenge is the value of time,” H.E. Al-Malik said. He also praised the objectives of FESCIOF and said that ICESCO will maximize the conference outcomes and “convert them into action.”
Farina highlighted the interdependence of the three sectors of education, culture, and science, stressing, “we cannot advance on education if we do not advance in science and in culture at the same time.”
Finally, H.E. Mohamed Ould Amar, Director General of ALECSO concluded that “the goals from this Forum are crystal clear, we are working together to achieve them.”
FESCIOF aims to establish a collaborative and trusted global platform for international organizations to come together and capitalize on future opportunities. The event fosters open dialogue and partnership among stakeholders to create a roadmap for international organizations to collaborate more effectively, while establishing a sustainable mechanism for partnerships resulting from the forum.
FESCIOF, which took place from 8-9 March, is jointly organized by the ALECSO and the SNC.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005847/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom